Spero Therapeutics Q1 Loss Narrows to $7.2M; $56.1M Cash Supports Runway into 2028
SPRO has more than doubled off its 52-week low of $0.61.
Summary
Spero Therapeutics reported a Q1 2026 net loss of $7.2 million, an improvement compared to a $13.9 million net loss in the same quarter last year. The company ended the quarter with $56.1 million in cash and cash equivalents, reiterating its guidance for a cash runway extending into 2028. While total revenue declined to $0.3 million from $5.9 million year-over-year, the significant reduction in R&D and G&A expenses contributed to the narrower loss. This financial update provides a current snapshot of the company's operational efficiency and liquidity, which is crucial for a development-stage biotech. The New Drug Application (NDA) for tebipenem HBr remains under FDA review with a PDUFA date of June 18, 2026, a detail previously disclosed in the company's 2025 10-K filing. Traders will be watching for the FDA decision on tebipenem HBr as the next major catalyst.
At the time of this announcement, SPRO was trading at $2.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $141.3M. The 52-week trading range was $0.61 to $3.22. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.